2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
Our blog on Weighted vests: the best weight loss hack explores how small changes can make a big metabolic impact
A minimum cycle of 12 weeks is recommended, with 16-24 weeks being common for advanced users
The Prevalence and Consequences of Support for Off-label Ozempic Prescriptions. Health Economics, Policy, and Law , 7 Jan
The 2025 systematic review noted that despite increasing clinical use, this level of evidence does not yet exist